Araris Biotech AG

Araris Biotech AG, a spin-off of the Paul Scherrer Institute (PSI) and ETH Zurich, is developing novel antibody-drug conjugates for targeted cancer chemotherapies. Araris’ technology enables the stable binding of active substances to antibodies, ensuring that the often highly aggressive cancer drugs take effect only in the intended areas of the body. Araris aims to make cancer treatment more effective while simultaneously being gentler for patients.